“Magic Mushrooms” may offer great comfort to Parkinson’s patients, as the study shows

like Parkinson’s cases Continue to rise, the race is running to combat the effects of the disease – the researchers have identified an unlikely relief source.

Psilocybin, a narcotic compound found in some mushrooms, was found to improve mood, perception and kinetic symptoms in Parkinson’s patients, according to a new study from the University of California San Francisco (UCSF).

The article, often referred to as “magic mushrooms”, has already been shown Dilution of depression The anxiety, which prompted researchers to explore its potential in Parkinson.

Anesthetic decline reports by 183 % in reservations, where health experts cite the “negative side” for irregular use

People with neurological disorder often suffer from a “mood defect” and do not tend to respond well to traditional antidepressants, according to a press statement in UCSF.

“Many people do not realize this, but Parkinson’s mood symptoms are linked to a faster physical decrease,” said the main study author, Eileen Bradley, Assistant Professor and Assistant Director of the UCSF, in the version.

“They are actually a stronger indication of patients The quality of life With Parkinson, their kinetic symptoms. “

The small study included 12 people with moderate Parkinson’s disease. It ranged at the age of 40 to 75. They all suffer from depression and/or anxiety.

FDA rejects MDMA as a drug treatment for mental health, PTSD

They all received a 10 mg dose of cellosipine, then a dose of 25 mg after two weeks. To measure antiquities, the participants met with Licensed Before and after receiving the medicine.

In one week and one month’s follow -up, patients have reported “large clinical improvements” not only in mood and perception, but also the function of the kinetic.

“Many people do not realize it, but the symptoms of the mood in Parkinson’s mood are linked to a faster decrease.”

“These results are really encouraging,” Bradley told Fox News Digital. “Depression and anxiety, which weakens many people who suffer from Parkinson’s, significantly – and these improvements lasted for at least three months after patients from the medicine.”

Amir Enamdar, a UK pharmaceutologist and chief medical official in Siben, indicated that the improvement in kinetic symptoms was somewhat surprising.

“The authors are noticed, this may be due to dopamine modification through the effect of cellosipine on many types of serotonin receptors.” (Inamdar did not participate in the study.)

The most common side effects of Singlosipine were anxiety, nausea, headache and High blood pressureBut none of them was serious enough to request medical care, according to researchers.

“Despite the difficult experiments reports of two participants, Celosipine seemed to have been well -endured,” Enamdar pointed out. “The side effects were consistent with what was seen in other studies, with no precipitation/ exacerbation Mental symptoms”

The study, published in neural drugs, is a nature of nature, by an unknown donor.

Restrictions and more research

This was the first study to measure the effects of anesthetic substance on patients with nervous degeneration, according to USCF.

Although this study was “an important first step”, Bradley noted that researchers could not extract conclusions from them, as it was a small pilot without a control group.

Click here to get the Fox News app

“We have now started a much larger experience designed to test strictly if Psilocybin is effective in Parkison’s,” she told Fox News Digital.

“We also collect multimedia biological data to understand how cylosipine works. This is crucial not only to improve cellosipine treatments, but also to direct the development of drug science from the next generation in the pipeline now and may be a promising for people with Parkinson.”

Click here to register in our health newsletter

Bradley still recommends that Parkinson’s patients approach Celosipine and Another drug With “a lot of caution”.

“I do not recommend patients with Parkinson’s that they start using Psilocybin,” she explained. “We are very early in this research, and we do not believe that these medications will be safe for all with the disease.”

“I hope people will continue to do so Defender of the search So we can accelerate the process of identifying the appropriate drug for the appropriate patient at the right time. “

Inamadar agreed that although the results were encouraged, the study was based on a small and limited sample.

For more health articles, please visit www.foxnews.com/health

“The study was also an open name, which gives higher expected effects, despite the improvements in the mood and Anxiety symptoms They are still watching in three months. “

“In general, () very encouraging results call for more investigation, and certainly an attempt to understand the mechanism behind the improvement in kinetic symptoms.”